VIRGO Consortium

Research Areas

Basic Research

At a Glance

- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: Dutch Life Sciences Health Sector
- Initiator Type: Government
- Location: Europe

Abstract

The VIRGO Consortium focuses on providing the infrastructure for virus discovery and for advancing knowledge of viruses and the mechanisms of mutual virus-host interactions, which feed into the subsequent development of novel interventions, diagnostics, and prognostics at the levels of both individual patients and populations. It provides valuable leads for the development of novel antiviral drugs, vaccines, and other therapeutics; treatment regimens; and guidance as well as prevention strategies.

Mission

VIRGO aims at an improved understanding of major acute and chronic viral diseases, such as influenza, hepatitis, and acquired immunodeficiency syndrome (AIDS). These viral diseases constitute the majority of infectious diseases in the Netherlands and beyond. VIRGO studies the interaction between viruses causing these diseases and their hosts at a molecular level.

VIRGO aims to develop new approaches to interfere in the infection processes, for example, to prevent infection by designing new or improved vaccines, or improve clinical management of viral
infections with novel diagnostic tools. To achieve these goals VIRGO unites the top research institutes in the field in the Netherlands.

**Financing**

VIRGO is a public-private partnership of seven academic institutions, three research organizations, and 10 private-sector companies that has received part of the sector-wide €81 million FES grant awarded to the Dutch Life Sciences and Health sector. In addition VIRGO is supported by NGI (Health Cluster) and the Dutch Ministry of Health. Together with NEUROBsik, VIRGO forms the DRUGS cluster.

**Links/Social Media Feed**

Homepage  http://virgo.nl/

**Points of Contact**

Wytemaweg 80, room Ee 17-51
3015 CN Rotterdam
The Netherlands
phone: +31 10 704 4770

**Sponsors & Partners**

AIMM Therapeutics
AMC – Medical Microbiology
Bristol-Myers Squibb (BMS)
Erasmus MC
F. Hoffman-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline
Leiden University
LUMC – Infectious Diseases
Netherlands Proteomics Center
Novavax AB
Psynova Neurotech
Radboud University Nijmegen Medical Center (RUNMC)
RIVM – Infectious Diseases
Thermo Scientific Dionex
UMC Utrecht
University of Groningen
Utrecht University
ViroClinics Biosciences
Vironovative

Updated: 04/08/2016